Multiomic analysis reveals a key BCAT1 role in mTOR activation by B cell receptor and TLR9.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40924473.
- Also identified by DOI 10.1172/JCI186258 and PMC identifier 12618069.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
B lymphocytes play major adaptive immune roles, producing antibodies and driving T cell responses. However, how immunometabolism networks support B cell activation and differentiation in response to distinct receptor stimuli remains incompletely understood. To gain insights, we systematically investigated acute primary human B cell transcriptional, translational, and metabolomic responses to B cell receptor (BCR), TLR9, CD40-ligand (CD40L), IL-4, or combinations thereof. T cell-independent BCR/TLR9 costimulation, which drives malignant and autoimmune B cell states, highly induced transaminase branched chain amino acid transaminase 1 (BCAT1), which localized to lysosomal membranes to support branched chain amino acid synthesis and mTORC1 activation. BCAT1 inhibition blunted BCR/TLR9, but not CD40L/IL-4-triggered B cell proliferation, IL-10 expression, and BCR/TLR pathway-driven lymphoma xenograft outgrowth. These results provide a valuable resource, reveal receptor-mediated immunometabolism remodeling to support key B cell phenotypes, and identify BCAT1 as an activated B cell therapeutic target.
Medical subject headings
- Receptors, Antigen, B-Cell
- Toll-Like Receptor 9
- B-Lymphocytes
- TOR Serine-Threonine Kinases
- Transaminases